Ultra-low dose rituximab controls disease activity for most rheumatoid arthritis patients in new study
New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab ...
Nov 2, 2021
0
5